Products - Metastases | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 176 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
15 June 2022
Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA1065)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 May 2025
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 May 2025
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal) (TA1052)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 April 2025
Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (TA1040)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 February 2025
Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment (TA1036)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 February 2025
Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) (TA1032)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 January 2025
Tebentafusp for treating advanced uveal melanoma (TA1027)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 January 2025
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 September 2024
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 July 2024
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (TA983)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 June 2024
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA976)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 May 2024
Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 February 2024
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 February 2024
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 February 2024
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA939)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 December 2023
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 November 2023
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 June 2023
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) (TA901)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 June 2023
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 May 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) (TA879)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 April 2023
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 February 2023
Regorafenib for previously treated metastatic colorectal cancer (TA866)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 February 2023
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments (TA862)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 February 2023
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments (TA852)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2022
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) (TA848)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 December 2022
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2022
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) (TA797)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 June 2022
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 May 2022
Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (TA786)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 April 2022
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 March 2022
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 February 2022
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) (TA750)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 December 2021
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 October 2021
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 October 2021
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) (TA730)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 September 2021
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 September 2021
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 August 2021
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 July 2021
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 July 2021
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 July 2021
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 June 2021
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies (TA704)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 May 2021
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 April 2021
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 April 2021
Published:
11 April 2018
Avelumab for untreated metastatic Merkel cell carcinoma (TA691)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 April 2021
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA684)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 March 2021
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA683)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 March 2021
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) (TA674)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 February 2021
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 January 2021
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 November 2020
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 October 2020
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 September 2020
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 August 2020
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 July 2020
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) (TA635)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 June 2020
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 June 2019
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 March 2019
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 February 2019
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 February 2019
Padeliporfin for untreated localised prostate cancer (TA546)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 November 2018
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 August 2018
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 July 2018
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 July 2018
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2018
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 May 2018
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 March 2018
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 March 2018
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 January 2018
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 December 2017
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 December 2017
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 November 2017
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
25 September 2017
Published:
29 March 2017
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
12 September 2017
Published:
25 November 2015
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
6 September 2017
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 August 2017
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 June 2017
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 April 2017
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) (TA240)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
29 March 2017
Published:
14 December 2011
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 December 2016
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 October 2016
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
24 August 2016
Published:
25 May 2016
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
27 July 2016
Published:
27 June 2012
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
27 July 2016
Published:
27 April 2016
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 July 2016
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2016
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 February 2016
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 January 2016
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) (TA334)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 February 2015
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 January 2015
Published:
12 December 2012
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 October 2014
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 July 2014
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 July 2014
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 April 2014
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 March 2014
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 January 2013
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 December 2012
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 October 2012
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 August 2012
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2012
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2 (TA257)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2012
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 January 2012
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 January 2012
Published:
24 January 2007
Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2011
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (TA214)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 February 2011
Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 December 2010
Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (TA209)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 November 2010
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 November 2010
Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (TA86)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 November 2010
Published:
27 October 2004
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 July 2010
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 August 2009
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 March 2009
Gemcitabine for the treatment of metastatic breast cancer (TA116)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 January 2007
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 June 2006
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 May 2003
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2025
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
24 July 2025
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 September 2025
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
11 September 2025
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 October 2025
Lifileucel for previously treated unresectable or metastatic melanoma ID3863
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 December 2025
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy [TSID10764]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
24 June 2025
Expected publication date:
TBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [TSID11810]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fruquintinib for previously treated metastatic colorectal cancer ID6274
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [TSID12044]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation [ID6535]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bevacizumab (Avastin and biosimilars) with fluoropyrimidine-based chemotherapy for untreated metastatic colorectal cancer [ID6465]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lutetium with androgen deprivation therapy and receptor pathway inhibitors for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID12195]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC